Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company also develops IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Frequently asked questions
What sector does Immunic Inc (IMUX) operate in?
Immunic Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Immunic Inc (IMUX) current stock price?
As of the latest data, Immunic Inc stock price is $7.61, with a previous close of $7.28. Immunic Inc gained $0.33 in the last trading session, representing a 4.53% increase.
What is Immunic Inc (IMUX) current market capitalization?
Immunic Inc market cap is approximately 103.83 million.
What is Immunic Inc (IMUX) Earnings Per Share (EPS)?
The trailing EPS is -$3.55, and the forward EPS is -$2.43.
What is Immunic Inc (IMUX) EBITDA?
Immunic Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -34.00 million.
Does Immunic Inc (IMUX) pay dividends?
No. Immunic Inc does not pay a dividend.
When is Immunic Inc (IMUX) next earnings report?
Immunic Inc is expected to release its next earnings report on September 30, 2026.
What is Immunic Inc (IMUX) beta (volatility) score?
Immunic Inc has a beta of 1.412, suggesting it is more volatile than the market.
